Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

Biotechnology • Healthcare • Brisbane, CA, United States • DAWN (NMS)

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

650 484 0899 1800 Sierra Point Parkway, Brisbane, CA 94005, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Day One Biopharma (DAWN) Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib) - Yahoo Finance
Yahoo Finance • Dec 15
Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026 - I'm Bullish (NASDAQ:DAWN) - Seeking Alpha
Seeking Alpha • Dec 18
Day One Biopharmaceuticals to Acquire Mersana Therapeutics - GlobeNewswire
GlobeNewswire • Nov 13
Day One Biopharmaceuticals (NASDAQ:DAWN) Nasdaq Index Biomarker Science - Kalkine Media
Kalkine Media • Jan 2
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
MarketBeat • Dec 8

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Day One Biopharmaceuticals, Inc. had layoffs?
No layoff events have been recorded for Day One Biopharmaceuticals, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Day One Biopharmaceuticals, Inc. have?
Day One Biopharmaceuticals, Inc. has approximately 184 employees.
What industry is Day One Biopharmaceuticals, Inc. in?
Day One Biopharmaceuticals, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Day One Biopharmaceuticals, Inc. a publicly traded company?
Yes, Day One Biopharmaceuticals, Inc. is publicly traded under the ticker symbol DAWN on the NMS. The company has a market capitalization of approximately $0.97 billion.
Where is Day One Biopharmaceuticals, Inc. headquartered?
Day One Biopharmaceuticals, Inc. is headquartered in Brisbane, CA, United States at 1800 Sierra Point Parkway, Brisbane, CA 94005, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.